27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
It has been claimed that semantic dementia (SD), the temporal variant of fronto-temporal dementia, is characterized by an across-the-board deficit affecting all types of conceptual knowledge. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The average age at onset of first symptoms was 57.8 years. 3 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The positive effects might be caused by the systematic and tailored individual way of information provisioning by DEM-DISC. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The clinical symptoms of dementia include difficulty with speech, poor short-term memory, and changes in behavior. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper reviews the characteristics of sleep disorders found in people at a greater risk of dementia: the elderly adult, patients with mild cognitive impairment (MCI) and those with neurodegenerative diseases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In October 2019, a Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
HIV dementia has an annual incidence of 7% after AIDS development and eventually affects 20% of all HIV-infected persons. 4 key findings →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The study population consisted of 54 million Medicare data Fee-for-Service (FFS) and Medicare Advantage enrollees aged ≥ 65; 5.3 million beneficiaries were diagnosed with ADRD, and 16.2% (n = 861,337) of beneficiaries diagnosed with ADRD resided in rural America. 4 key findings →
Participants: 861,337 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is an incurable disease. The most promising advances in treatment include cholinesterase inhibitors and memantine. 1 key finding →
Design: cohort study Participants: 35,102 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The national prevalence and incidence of registered dementia diagnoses was 3.0% and 0.5%, respectively. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Annual Wellness Visit utilization was associated with an increased probability of new dementia diagnosis with effects varying by racial group (categorized as white, black, Hispanic/Latino, or Asian based on Social Security Administration data). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fifteen experts, with a mean professional experience of 25 ± 10 years, reached a consensus in the fourth round. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A positive family history was reported in 42% of patients in the Alzheimer disease cohort, 48% of patients in the frontotemporal dementia cohort, and 34% in those with other dementia types. 5 key findings →
Participants: 701 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) and vascular dementia (VaD) together contribute to almost 90 % of all dementia cases leading to major health challenges of our time with a substantial global socioeconomic burden. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Here we show, psychiatric behavioural symptoms and difficulties in activities of daily living, fluctuate alongside cognitive decline. 677 activities of daily living and 632 psychiatric behaviour questionnaires are available at intervals of 3 months. 5 key findings →
Participants: 141 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
"Sundowning syndrome" refers to the evening decline in mental state among cognitively impaired patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite progress in involving people living with dementia in health research, disparities remain, particularly in the field of health economics and outcomes research, where excessive reliance on proxy reports from care partners or healthcare professionals persists even when people are capable of self-reporting, leading to inequitable inclusion. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 2021, dementia accounted for 56.9 million global cases, 2.0 million deaths, and 36.3 million DALYs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global age-standardised DALY rates of ADRDs per 100 000 population slightly increased from 1331.59 (95% confidence interval (CI) = 881.57, 1781.61) in 1990 to 1347.24 (95% CI = 906.36, 1788.12) in 2021, with an AAPC of 0.04% (95% CI = 0.02, 0.05). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundPopulation ageing in Africa will increase the burden of Alzheimer's disease and related dementias within the next few decades. 1 key finding →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 88 participants were included in the study. 5 key findings →
Design: cross-sectional Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The overall rate of dementia was higher in PLHIV than that in POHIV (22% vs 10%; p = 1.4e). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This article synthesizes findings, from the Autism/Dementia Work Group of the 2nd International Summit on Intellectual Disabilities and Dementia, on the nature of autism/autism spectrum disorder and later-age neuropathologies, particularly dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundElectroencephalogram (EEG) is a promising, non-invasive method for identifying the presence of Alzheimer's disease (AD) by recognizing specific brain activity patterns associated with the disease. 3 key findings →
Participants: 431 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundDementia disorders are affecting millions of people globally, characterized by memory loss, communication difficulties, and motor function decline. 1 key finding →
Participants: 64 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,233 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →